At Exosome Sciences, we are working in collaboration with our majority shareholder, Aethlon Medical (Nasdaq:AEMD), to discover exosome-based biomarkers to diagnose and monitor Alzheimer's disease (AD), Chronic Traumatic Encephalopathy (CTE) and other neurological disorders. Our TauSome™ biomarker (also referred to as exosomal tau) is being studied as the basis for a blood-based test to identify CTE through the DETECT Study being conducted by the Boston University CTE Center.  At present, CTE can only be definitively diagnosed through post-mortem examination of brain tissue.

TauSome™ detection and the use of a TauSome™ biomarker to identify and monitor CTE and other neurological disorders are protected by multiple patent applications.


Aethlon Medical CEO Jim Joyce Discusses CTE Research Being Conducted by Aethlon's Exosome Sciences Subsidiary read more...

Our TauSome™ biomarker is being studied as the basis for a blood-based test to identify CTE through the DETECT (Diagnosing and Evaluating Traumatic Encephalopathy Using Clinical Tests) study being conducted by....
Click here to learn more


Chronic Traumatic Encephalopathy (CTE) is a disease of the brain found in athletes, military veterans, and others with a history of repetitive head impacts. This type of trauma can trigger...
Click for more


Not long ago, CTE was considered an obscure and not well-defined disease. A pivotal moment that propelled CTE into the spotlight occurred when researchers at the Boston University (BU) CTE Center conducted a press conference during the week of Super Bowl XLIII in 2009.
Click for more